A very severe health dilemma awaits the world, as bacterial infections have become more resistant to antibiotics, and experts warn that this global health crisis may claim the lives of millions of people in the near future, according to medical researcher Phyllis Arthur.
The researcher added in an article on the American Hill website that, according to a report published by the scientific journal The Lancet, antibiotic resistance is expected to contribute to about 170 million deaths worldwide within the next 25 years.
According to Felice, the main problem is that bacterial infections are becoming more resistant to treatment with conventional antibiotics. It is estimated that one in every six bacterial infections has become resistant to antibiotics, which further complicates the treatment of many infectious diseases.
commerce
The author explained that this gap between rapidly evolving microflora and declining antibiotic production lines may open the way to greater health disasters in the future.
She said that developing new antibiotics is the only solution, noting that this research faces several challenges.
In 2024, for example, work was underway to develop new antibiotics, but only five out of 90 were effective against pathogens classified by the World Health Organization as “critical priority.”
Phyllis says that the lack of innovation and finding solutions is due to the economic constraints facing pharmaceutical companies in developing new antibiotics, because they are unable to make a real profit from selling them.
Studies indicate that drug-resistant bacteria currently cause the death of more than one million people annually in the world
She explained that the excessive use of traditional antibiotics has led to an increase in bacterial resistance, as microbes adapt to the drugs over time and become more difficult to treat.
Studies indicate that drug-resistant bacteria currently cause the death of more than one million people annually in the world.
According to some estimates, the development of a single antibiotic can take more than 10 years at a cost of more than $1 billion, while the proceeds from the sale can be negative $50 million.
As a result of these circumstances, major companies have withdrawn from the antibiotic development market, while small companies are still struggling to survive.